BOSTON, Mass. and GENEVA, Switzerland – PHT Corporation announced the selection of the Hewlett Packard (HP) ElitePad 1000 G2 with Windows 8.1 for its SitePad® System. The SitePad System replaces paper data collection methods in clinical trials that collect clinician- and patient-reported outcomes for supporting label claims of new drugs. PHT is the leading provider of mobile apps used to collect patient-driven eData for clinical research.
The SitePad System is used to collect clinician-driven endpoints such as disease progression, impression and assessments as well as patient reported outcomes and quality of life data directly from patients. The SitePad is configured to the requirements of clinical protocols and the study specific data collected is sent securely to StudyWorks™, the PHT online portal that provides real-time information about study compliance plus key measures used for operations and patient safety monitoring. Protocol compliance with the SitePad System exceeds 98.5% historically over 130 trials.
Demand for the PHT SitePad System has been growing steadily in recent years across therapeutic areas including oncology, immunology, and CNS. Clients are using the SitePad to increase the quality and efficiency of both patient and clinician reported outcomes across indications and do not want paper to be a rate limiting step in the clinical trial process. The SitePad System delivers higher quality data and faster time to data analysis for clinical trial sponsors. Watch a brief video: http://bit.ly/1cpCXcl
Sheila Rocchio, PHT Vice President of Marketing and Corporate Strategy, commented, “Sponsors and CROs rely on the SitePad System for trials of all types because it offers a reliable, easy-to-use and regulatory compliant method for increasing data quality and protocol compliance. The SitePad System supports risked based monitoring strategies by providing real-time access to endpoint data and has been proven to significantly reduce monitoring and data management costs. In a recent Phase III trial, using the SitePad was 30% more cost effective than using paper.”
The HP ElitePad 1000 G2 contains an Intel® 64-bit Atom processor. It weighs 1.5 lbs and is one of the thinnest tablets in the industry, at 9.2 mm. Features include wider viewing angles on the outdoor-viewable 10.1-inch diagonal WUXGA multi-touch panel; wireless connection, including optional worldwide 4G LTE with HP Connection Manager; and, support for touch, pen or voice-based input. The HP ElitePad 1000 G2 offers enhanced protection against virus attack, with a design that helps prevent data loss and reduce downtime.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.